In a report published Thursday, Brinson Patrick initiates coverage on NeoStem NBS with a Market Outperform and $6 price target.
In the report Brinson Patrick wrote, "NeoStem is developing an active portfolio of product candidate assets based on the company's diverse array of technology platforms and leading adult stem cell products that target blockbuster market opportunities. We believe the company's business components, Amorcyte,
Athelos, VSEL, and stem cell banking, position NeoStem at the forefront of shifting paradigms and advancements in the stem cell industry."
Share of NeoStem closed at $0.53 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in